Long-term interferon treatment in metastatic renal cell carcinoma.
20 patients with progressive metastatic renal cell carcinoma entered a trial in which the effect of a long-term 6-month regimen of recombinant interferon alpha-2b (rIFN) was studied. 15 patients were evaluable. 4 remissions were detected: 1 complete, and 3 partial. All remissions were seen within 3 months of the start of treatment. We conclude that a 3-month rIFN treatment in metastatic renal cell carcinoma is sufficient to make a distinction between responders and non-responders. A review of the recent literature supports this conclusion.
Levens
W
W
Urology Department, University Clinic Aachen, FRG.
Rübben
H
H
Ingenhag
W
W
D000368:Aged; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012074:Remission Induction; D013997:Time Factors
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins